Jazz Pharmaceuticals (JAZZ) PT Raised to $225 at BofA Securities
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $225.00 (from $217.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
